Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Program Rollover Study
2024-514274-46-00Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, open-label trial of avelumab in Nonhematologic neoplasms (3 arms), sponsored by Merck KGaA. Primary endpoint: Long-term safety. Started Jun 2019; status: completed.
02
Drugs
avelumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-514274-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514274-46-00.